Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus Neoformans

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2011 Sep 17

PMID 21922016

Citations 22

Authors

Oscar Zaragoza

Affiliations

Soon will be listed here.

Abstract

Although morphological transitions (such as hyphae and pseudohyphae formation) are a common feature among fungi, the encapsulated pathogenic yeast Cryptococcus neoformans is found during infection as blastoconidia. However, this fungus exhibits striking variations in cellular structure and size, which have important consequences during infection. This review will summarize the main aspects related with phenotypic and morphological variations in C. neoformans, which can be divided in three classes. Two of them are related to changes in the capsule, while the third one involves changes in the whole cell. The three morphological and phenotypic variations in C. neoformans can be classified as: (1) changes in capsule structure, (2) changes in capsule size, and (3) changes in the total size of the cell, which can be achieved by the formation of cryptococcal giant/titan cells or microforms. These changes have profound consequences on the interaction with the host, involving survival, phagocytosis escape and immune evasion and dissemination. This article will summarize the main features of these changes, and highlight their importance during the interaction with the host and how they contribute to the development of the disease.

Citing Articles

Assessing the In Vitro Potential of Glatiramer Acetate (Copaxone) as a Chemotherapeutic Candidate for the Treatment of Infection.

Alves V, Martins P, Miranda B, Andrade I, Pereira L, Maeda C J Fungi (Basel). 2023; 9(8).

PMID: 37623554 PMC: 10455304. DOI: 10.3390/jof9080783.

Capsule-Deficient Cryptococcal Meningitis: A Diagnostic Conundrum.

Shende T, Singh G, Xess I, Khullar S, Yadav R, Agarwal R J Glob Infect Dis. 2023; 14(4):165-169.

PMID: 36636299 PMC: 9831207. DOI: 10.4103/jgid.jgid_255_21.

A dissemination-prone morphotype enhances extrapulmonary organ entry by Cryptococcus neoformans.

Denham S, Brammer B, Chung K, Wambaugh M, Bednarek J, Guo L Cell Host Microbe. 2022; 30(10):1382-1400.e8.

PMID: 36099922 PMC: 9588642. DOI: 10.1016/j.chom.2022.08.017.

Fungal infections: Pathogenesis, antifungals and alternate treatment approaches.

Reddy G, Padmavathi A, Nancharaiah Y Curr Res Microb Sci. 2022; 3:100137.

PMID: 35909631 PMC: 9325902. DOI: 10.1016/j.crmicr.2022.100137.

Lineages Derived from Cryptococcus neoformans Type Strain H99 Support a Link between the Capacity to Be Pleomorphic and Virulence.

Fernandes K, Fraser J, Carter D mBio. 2022; 13(2):e0028322.

PMID: 35258331 PMC: 9040854. DOI: 10.1128/mbio.00283-22.

References

Guerrero A, Jain N, Wang X, Fries B . Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect Immun. 2010; 78(3):1049-57. PMC: 2825907. DOI: 10.1128/IAI.01049-09. View

Nimrichter L, Frases S, Cinelli L, Viana N, Nakouzi A, Travassos L . Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell. 2007; 6(8):1400-10. PMC: 1951138. DOI: 10.1128/EC.00122-07. View

Rodrigues M, Nimrichter L, Oliveira D, Frases S, Miranda K, Zaragoza O . Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell. 2006; 6(1):48-59. PMC: 1800364. DOI: 10.1128/EC.00318-06. View

Zaragoza O, Garcia-Rodas R, Nosanchuk J, Cuenca-Estrella M, Rodriguez-Tudela J, Casadevall A . Fungal cell gigantism during mammalian infection. PLoS Pathog. 2010; 6(6):e1000945. PMC: 2887474. DOI: 10.1371/journal.ppat.1000945. View

van de Moer A, Salhi S, CHERNIAK R, Pau B, Garrigues M, Bastide J . An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan. Res Immunol. 1990; 141(1):33-42. DOI: 10.1016/0923-2494(90)90099-k. View

Lipovsky M, Tsenova L, Coenjaerts F, Kaplan G, CHERNIAK R, Hoepelman A . Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis. J Neuroimmunol. 2000; 111(1-2):10-4. DOI: 10.1016/s0165-5728(00)00354-4. View

Garcia-Rodas R, Casadevall A, Rodriguez-Tudela J, Cuenca-Estrella M, Zaragoza O . Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One. 2011; 6(9):e24485. PMC: 3168503. DOI: 10.1371/journal.pone.0024485. View

Zaragoza O, Telzak A, Bryan R, Dadachova E, Casadevall A . The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol. 2005; 59(1):67-83. DOI: 10.1111/j.1365-2958.2005.04928.x. View

Levitz S, Nong S, Seetoo K, Harrison T, Speizer R, Simons E . Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun. 1999; 67(2):885-90. PMC: 96400. DOI: 10.1128/IAI.67.2.885-890.1999. View

10.

French M . HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2008; 48(1):101-7. DOI: 10.1086/595006. View

11.

Singh N, Forrest G . Cryptococcosis in solid organ transplant recipients. Am J Transplant. 2010; 9 Suppl 4:S192-8. DOI: 10.1111/j.1600-6143.2009.02911.x. View

12.

De Jesus M, Nicola A, Chow S, Lee I, Nong S, Specht C . Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence. 2010; 1(6):500-8. PMC: 3073359. DOI: 10.4161/viru.1.6.13451. View

13.

Hosseini-Moghaddam S, Husain S . Fungi and molds following lung transplantation. Semin Respir Crit Care Med. 2010; 31(2):222-33. DOI: 10.1055/s-0030-1249118. View

14.

Okagaki L, Wang Y, Ballou E, OMeara T, Bahn Y, Alspaugh J . Cryptococcal titan cell formation is regulated by G-protein signaling in response to multiple stimuli. Eukaryot Cell. 2011; 10(10):1306-16. PMC: 3187071. DOI: 10.1128/EC.05179-11. View

15.

Gates-Hollingsworth M, Kozel T . Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule. Mol Microbiol. 2009; 74(1):126-138. PMC: 2788819. DOI: 10.1111/j.1365-2958.2009.06855.x. View

16.

Chrisman C, Albuquerque P, Guimaraes A, Nieves E, Casadevall A . Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog. 2011; 7(5):e1002047. PMC: 3102711. DOI: 10.1371/journal.ppat.1002047. View

17.

Kozel T, Gulley W, Cazin Jr J . Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun. 1977; 18(3):701-7. PMC: 421292. DOI: 10.1128/iai.18.3.701-707.1977. View

18.

Ellerbroek P, Hoepelman A, Wolbers F, Zwaginga J, Coenjaerts F . Cryptococcal glucuronoxylomannan inhibits adhesion of neutrophils to stimulated endothelium in vitro by affecting both neutrophils and endothelial cells. Infect Immun. 2002; 70(9):4762-71. PMC: 128235. DOI: 10.1128/IAI.70.9.4762-4771.2002. View

19.

Anna E . Rapid in vitro capsule production by cryptococci. Am J Med Technol. 1979; 45(6):585-8. View

20.

CHERNIAK R, Jones R, Slodki M . Type-specific polysaccharides of Cryptococcus neoformans. n.m.r.-spectral study of a glucuronomannan chemically derived from a Tremella mesenterica exopolysaccharide. Carbohydr Res. 1988; 182(2):227-39. DOI: 10.1016/0008-6215(88)84005-9. View